iRhythm Technologies, Inc. (IRTC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Quentin S. Blackford | President, CEO & Director | 1.42M | -- | 1979 |
| Mr. Brice Bobzien CPA | Chief Financial Officer | 715.24k | -- | 1979 |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Product Innovation | 749.18k | -- | 1974 |
| Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 766.93k | -- | 1979 |
| Mr. Chad M. Patterson | Chief Commercial Officer | 836.55k | -- | 1982 |
| Mr. Mervin Smith | Executive Vice President of Business Operations | -- | -- | 1975 |
| Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | -- | -- | 1972 |
| Mr. Mark J. Day Ph.D. | Chief Technology Officer | 718.76k | 1.28M | 1971 |
| Mr. Daniel G. Wilson | Executive VP of Corporate Development & Investor Relations | 670.09k | -- | 1982 |
| Mr. Douglas J. Devine | Executive Advisor | 800k | -- | 1970 |
iRhythm Technologies, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 2,000
Description
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Corporate Governance
Recent Events
- Apr 11, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Mar 28, 2024PRE 14A: Proxy StatementsSee Full Filing
- Mar 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 05, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing